Viridian Therapeutics, Inc.\DE (VRDN) Long-Term Debt Issuances (2013 - 2022)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Long-Term Debt Issuances of -$15.0 million for Q4 2023, down 3463.23% year-over-year from $446000.0 in Q4 2022, and down 3463.23% quarter-over-quarter from $446000.0 in Q4 2022.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Long-Term Debt Issuances (2013 - 2022) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Long-Term Debt Issuances history runs 7 years deep, the most recent figure standing at -$15.0 million for Q4 2023.
- In Q4 2023, Long-Term Debt Issuances fell 3463.23% year-over-year to -$15.0 million; the TTM figure through Dec 2024 stood at -$14.6 million (up 2.97% YoY), while the FY2025 annual figure was $28.9 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q4 2023 stood at -$15.0 million, down from $446000.0 in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $8.6 million in Q4 2020, with the low at -$15.0 million in Q4 2023.
- The 4-year median for Long-Term Debt Issuances is $726000.0 (2020), against an average of -$482000.0.
- Peak annual rise in Long-Term Debt Issuances reached 3463.23% in 2023, while the deepest fall reached 3463.23% in 2023.
- Viridian Therapeutics, Inc.\DE's Long-Term Debt Issuances stood at $1.3 million in 2019, then jumped by 542.69% to $8.6 million in 2020, then sank by 94.79% to $446000.0 in 2022, then sank by 3463.23% to -$15.0 million in 2023.
- Business Quant data shows VRDN's Long-Term Debt Issuances at -$15.0 million in Q4 2023, $446000.0 in Q4 2022, and -$446000.0 in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 446,000.00 |
| Jun 30, 2022 | -446,000.00 |
| Dec 31, 2020 | 8.57 Mn |
| Jun 30, 2020 | 726,000.00 |
| Mar 31, 2020 | 1.00 Mn |
| Sep 30, 2019 | 1.33 Mn |
| Jun 30, 2019 | 333,000.00 |
| Dec 31, 2017 | 8.50 Mn |
| Sep 30, 2017 | 500,000.00 |
| Jun 30, 2017 | 500,000.00 |
| Mar 31, 2017 | 500,000.00 |
| Dec 31, 2016 | 333,000.00 |
| Jun 30, 2014 | 695,000.00 |
| Mar 31, 2014 | 100,000.00 |
| Dec 31, 2013 | 749,817.00 |
| Sep 30, 2013 | 601,456.00 |